



**PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF
2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS
(THE “TRANSPARENCY LAW”)**

GHENT, Belgium, 15 February 2018 – **Ablynx [Euronext Brussels and Nasdaq: ABLX]** today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the “Transparency Law”), that it received a notification of shareholdings from Van Herk Investments B.V. on 14 February 2018.

Van Herk Investments B.V. notified Ablynx that it has downward crossed the 10% threshold on 12 February 2018 and now holds 7,451,158 voting securities of Ablynx, representing 9.93% of the current 75,065,990 outstanding voting rights of Ablynx (versus 10.21% notified previously on 15 January 2018).

The notification contains the following information:

- **Reason for the notification:** acquisition or disposal of voting securities or voting rights
- **Notification by:** a parent undertaking or a controlling person
- **Persons subject to the notification requirement:** Mr. A. van Herk, Van Herk Investments B.V.
- **Transaction date:** 12 February 2018
- **Threshold that is crossed:** 10%
- **Denominator:** 75,065,990
- **Details of the notification:** Van Herk Investments B.V. holds 7,451,158 voting securities of Ablynx
- **Chain of controlled undertakings through which the holding is effectively being held:** Van Herk Investments B.V. is controlled by Mr. A. van Herk in accordance with Articles 5 and 7 of the Dutch Companies Code.

A full version of the transparency notification is available on Ablynx website, under the section [Investors](#).

The articles of the association of Ablynx NV provide for shareholders notification threshold of 3%, 5% or a multiple of 5% of the total number of existing voting rights.

About Ablynx

[Ablynx](#) is a biopharmaceutical company engaged in the development of [Nanobodies](#), proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than [45 proprietary and partnered programmes](#) in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx

Dr Edwin Moses

CEO

t: +32 (0)9 262 00 07

m: +32 (0)473 39 50 68

e: edwin.moses@ablynx.com

Lies Vanneste

Director IR

t: +32 (0)9 262 0137

m: +32 (0)498 05 35 79

e: lies.vanneste@ablynx.com



@[AblynxABLX](https://twitter.com/AblynxABLX)

Ablynx media relations:

Consilium Strategic Communications

Mary-Jane Elliott, Philippa Gardner, Sukaina Virji

t: +44 (0)20 3709 5700

e: ablynx@consilium-comms.com

Joele Frank, Wilkinson Brimmer Katcher

Dan Katcher or Joseph Sala

t: +1 212-355-4449